We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
West African | LSE:WAFM | London | Ordinary Share | VGG9544K1021 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.25 | 1.00 | 1.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMWAFM
RNS Number : 3510K
West African Minerals Corporation
06 July 2017
For immediate release
6 July 2017
West African Minerals Corporation
("West African" or the "Company")
Board Appointment
The Board of West African Minerals Corporation is pleased to announce that Dr Kunwar Shailubhai has been appointed as non-executive director of the Company with immediate effect.
Dr Kunwar Shailubhai is Chief Executive Officer of AIM-traded Tizania Life Sciences Plc and has extensive experience within the life sciences sector, drawing on 30 years of experience in research and development of drug candidates for treatment of gastrointestinal disorders, inflammatory diseases and cancers. He previously worked for a number of years at Synergy Pharmaceuticals Inc (SGYP: NASDAQ), which he co-founded and where he served as chief scientific officer since 2008.
Dr Kunwar Shailubhai's pioneering research programme culminated in the development of the drug Trulance(TM) (plecanatide) which received FDA approval in January 2017 for the treatment of adults with chronic idiopathic constipation. A supplemental new drug application has been submitted for FDA review of Trulance for the treatment of adults with irritable bowel syndrome with constipation (IBS-C). Prior to joining Tiziana Life Sciences Plc and Synergy Pharmaceuticals Inc, Dr Kunwar Shailubhai worked at Callisto Pharmaceuticals, Monsanto Company and as a senior staff fellow at the National Institutes of Health (NIH).
AIM Disclosures
Further disclosures on Dr Kunwar Shailubhai as required under Schedule Two, paragraph (g) (i)-(viii) of the AIM Rules for Companies are as follows:
Dr Kunwar "Shailu" Shailubhai, aged 59, has held the following directorships and / or partnerships in the previous five years:
Current Past ------------------------ ----- Tiziana Life Sciences n.a. Plc Rasna Therapeutics Inc GenSignia Life Sciences Inc
There are no further disclosures in relation to Dr Kunwar Shailubhai pursuant to Schedule 2(g) of the AIM Rules for Companies.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information contact:
West African Minerals Corporation Gerard Holden +44 (0) 1624 639 396 Roland Cornish Beaumont Cornish Limited (Nominated Adviser) Michael Cornish +44 (0)20 7628 3396 Beaufort Securities Limited (Broker) Jon Belliss +44 (0)20 7382 8300
ENDS
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADMGGNZVKGNZM
(END) Dow Jones Newswires
July 06, 2017 08:47 ET (12:47 GMT)
1 Year West African Chart |
1 Month West African Chart |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions